Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2003-10-07
2011-10-25
Minnifield, Nita M (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C536S022100
Reexamination Certificate
active
08043622
ABSTRACT:
The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for inhibiting or treating inflammatory lung disease by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
REFERENCES:
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 6214806 (2001-04-01), Krieg et al.
patent: 7094766 (2006-08-01), Gilchrest et al.
patent: 2003/0087848 (2003-05-01), Bratzler et al.
patent: 2004/0132682 (2004-07-01), Klinman et al.
patent: 2004/0248834 (2004-12-01), Klinman et al.
patent: 2006/0074039 (2006-04-01), Klinman et al.
patent: 0 092 574 (1992-04-01), None
patent: WO 83/01451 (1983-04-01), None
patent: WO/93/23572 (1993-11-01), None
patent: WO 95/26204 (1995-09-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 98/11211 (1998-03-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 03/027313 (2003-04-01), None
patent: WO 2004/012669 (2004-02-01), None
Broide et al 1998. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J. Immunol. 161: 7054-7062.
Bernard G Am J Respir Crit Care Med. Oct. 1, 2005;172(7):798-806. Epub Jul. 14, 2005.
Van der Vliet A, Eiserich JP, Cross CE 2000. Nitric oxide: a pro-inflammatory mediator in lung disease? Respir Res 1: 67-72.
Matthay MA, Zimmerman GA, Esmon C, et al. Future research directions in acute lung injury:summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2003;167:1027-1035.
Goldberg, B, Urnovitz, HB, Stricker, RB: Beyond danger: Unmethylated CpG dinucleotides and the immunopathogenesis of disease. Immunol Lett 2000 73:13-18.
Heeg K, Zimmermann S. CpG DNA as a Th1 trigger [Review]. Int Arch Allergy Immunol 2000;121:87-97.
Battegay, “Angiogenesis: mechanistic insignts, neovascular diseases, and therapeutic prospects,”J. Molec. Med. 73(7): 333-346, 1995.
Beck et al., “Vascular development: cellular and molecular regulation,”FASEB J. 11(5):365, 1997.
Bjersing et al., “Anti-proliferative effects of phosphodiester oligodeoxynucleotides,”Immunobiology, 209(8):637-45, 2004.
Braun et al.,“On the Difficulties of Establishing a Consensus on the Definition of and Diagnostic Investigations for Reactive Arthritis,”J. Rheumatol. 27:2185-2192, 2000.
Britigan et al., “Lactoferrin Binds CpG-Containing Oligonucleotides and Inhibits Their Immunostimulatory Effects on Human B Cells,”J. Immunol. 167:2921-2928, 2001.
Chen et al., “Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs,”Gene Ther. 8(13):1024-1032, 2001.
Deng et al., “Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis,”Nat. Med. 5:702-705, 1999.
Deng et al., “Synovial cytokine mRNA expression during arthritis triggered by CpG motifs of bacterial DNA,”Arthritis Res. 3(1):48-53, 2001.
Deng et al., “The Features of Arthritis Induced by CpG Motifs in Bacterial DNA,”Arthritis Rheum. 43:356-364, 2000.
Gaudric et al. “Quantification of Angiogenesis due to Basic Fibroblast Growth Factor in a Modified Rabbit Corneal Model,”Ophthal. Res. 24: 181, 1992.
Gursel et al., “Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides,”J. Immunol. 167: 3324, 2001.
Gürsel et al., “Differential and competitive activiation of human immune cells by distinct classes of CpG oligodeoxynucleotide,”J. Leuko.Biol. 71:813-820, 2002.
Han et al., “G-quadruplex DNA: a potential target for anti-cancer drug design,”Trends Pharmacol. Sci. 21:136-142, 2000.
Hartmann et al., “CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells,”Proc. Natl. Acad. Sci. USA96:9305-9310, 1999.
Ho et al., “An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems,”J. Immunol. 171:4920-4926, 2003.
Kenyon et al., “A Model of Angiogenesis in the Mouse Cornea,”Invest Opthalmol. Vis. Sci. 37:1625-1632, 1996.
Klinman et al., “CpG Motifs present in bacterial DNA rapdily induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ,”Proc. Natl. Acad. Sci. USA 93:2879, 1996.
Klinman et al., “Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines,”J.Immunol. 158:3635-3639, 1997.
Klinman et al., “Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety,”Springer•Semin. Immunopathol. 22:173-183, 2000.
Krieg et al., “CpG motifs in bacterial DNA trigger direct B-cell activation,”Nature374:546-549, 1995.
Krieg, “Commentary: A possible cause of joint destruction in septic arthritis,”Arthritis Research1(1):3-4, 1999.
Krieg, “From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA,”Antisense Nucleic Acid Drug Dev11(3):181-188; 2001.
Krieg et al., “Enhancing vaccines with immune stimulatory CpG DNA,”Curr Opin Mol Ther3(1):15-24, 2001.
Krieg, “From A to Z on CpG,”Trends Immunol. 23(2):64-65, 2002.
Krieg, “CpG Motifs in bacterial DNA and their immune effects,”Annu Rev Immunol20:709-760, 2002.
Lenert et al., “CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonuceotides at a site proximal to NF-kappaB activation.”Antisense Nucleic Acid Drug Dev11(4):247-256, 2001.
Liang et al., “Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides,”J. Clin. Invest. 98:1119-1129, 1996.
Lichtenberg et al., “The Rat Subcutaneous Air Sac Model: A Quantitative Assay of Antiangiogenesis in Induced Vessels,”Pharmacol Toxicol. 84:34-40, 1999.
Murchie et al., “Tetraplex folding of telomere sequences and the inclusion of adenine bases,”EMBO J. 13:993-1001, 1994.
Pisetsky et al., “Immunological Properties of Bacterial DNA,”NY Acad. Sci. 772:152-163, 1995.
Pisetsky et al., “Inhibition of Murine Macrophage IL-12 Production by Natural and Synthetic DNA,”Clin. Immunol. 96, 198-204, 2000.
Quarcoo et al., “Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity,”J Allergy Clin Immunol., 114(2):288-95, 2004.
Roman et al., “Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants,”Nature Medicine3(8):849-854, 1997.
Stunz et al., “Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells,”Eur J Immunol32(5):1212-1222; 2002.
Verthelyi et al., “Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs,”J. Immunol. 166:2372-2377, 2001.
Vialas et al., “Oxidative Damage Generated by an Oxo-Metalloporphyrin onto the Human Telomeric Sequence,”Biochemistry39:9514-9522, 2000.
Wilting et al., “A modified chorioallantoic membrane (CAM) assay for qualitative and quantitative study of growth factors,”Anat. Embryol. 183: 259-271, 1991.
Yamada et al., “Effect of Suppressive DNA on CpG-Induced Immunce Activation,”J. Immunol. 169:5590-5594, 2002.
Yamamoto et al., “Unique Pallindromic Sequences in Synthetic Oligonucleotides are Required to Induce INF and Augment INF-Mediated Natural Killer Activity,”J. Immunol. 148:4072-4076, 1992.
Yi et al., “Rapid Immune Activation by CpG Motifs in Bacterial DNA,”J. Immun. 157:5394-5402, 1996.
Zeuner et al., “Reduction of Cp
Klinman Dennis M.
Yamada Hiroshi
Archie Nina
Klarquist & Sparkman, LLP
Minnifield Nita M
The United States of America as represented by the Secretary of
LandOfFree
Method of treating inflammatory lung disease with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating inflammatory lung disease with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating inflammatory lung disease with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4255821